Remicade patent rejected by Patent & Trademark Office - Johnson & Johnson
February 2015-Johnson & Johnson announced receipt of a further action from the Patent and Trademark Office regarding the re-examination of U.S. Patent No. 6,284,471 ('471) relating to Remicade issuing a final rejection of the patent. J&J has sixty days to respond to this action and will do so. Currently the '471 patent expires in September 2018. J&J believes the '471 patent is valid and, if necessary, will pursue all available appeals.
Comment: The patent rejection could open the Remicade to biosimilar competition as early as next year particularly from Celltrion which has its biosimilar infliximab now under FDA review.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.